Scott Chudnoff, MD, highlights the benefits of Fembloc for permanent contraception

In a recent interview with Contemporary OB/GYN, Scott G. Chudnoff, MD, chair of obstetrics and gynecology at Maimonides Health, discussed the significance of the FDA’s Investigational Device Exemption (IDE) for FemBloc, a novel transcervical option for permanent birth control, as well as the supporting data and expected next steps.^1,2

Chudnoff explained that the IDE is essential for conducting FemBloc’s pivotal clinical trial, a requirement for FDA approval. Prior to the current study, 3 earlier clinical trials had evaluated the device, all demonstrating a strong safety profile.

According to Chudnoff, no serious adverse events occurred in these earlier trials, and the minor side effects—such as cramping, spotting, or mild bleeding—were consistent with what clinicians anticipate from a transcervical procedure. Importantly, he noted that no pregnancies were reported when the follow-up confirmation test verified successful occlusion of both fallopian tubes, reinforcing the device’s potential efficacy.

FemBloc represents a meaningful advancement in permanent contraception because it eliminates several traditional barriers associated with surgical sterilization. Chudnoff emphasized that FemBloc requires no incisions, no general anesthesia, and leaves no permanent implant behind.

It is nonhormonal and designed for quick recovery, making it an option that aligns closely with what many patients and clinicians consider an ideal permanent contraceptive method. He highlighted the simplicity of an “in-and-out” office-based experience combined with a low-risk profile and encouraging effectiveness data from earlier studies.

Regarding the device’s development, Chudnoff reported that FemBloc is currently in the final phase of its pivotal trial following recent FDA approval to proceed. If outcomes align with expectations, he anticipates that the product will become available on the US market once the trial is complete.

From a consumer standpoint, FemBloc could offer several significant benefits. Because it is an office-based procedure, it may substantially reduce overall costs compared with traditional sterilization, which typically requires an operating-room setting. Lower copays and reduced logistical burdens may improve access for patients seeking reliable permanent contraception.

Additionally, demand for nonhormonal options continues to grow, reflecting a broader patient preference to avoid hormone-related side effects. Chudnoff stated that the medical community recognizes this need and views FemBloc as a promising solution.

In closing, Chudnoff expressed optimism about FemBloc’s progress and potential impact. Having worked with the product over time, he noted a “palpable excitement” as it approaches possible market availability, drawing parallels to the enthusiasm that accompanied earlier transcervical contraceptive innovations.

No relevant disclosures.

References

1. Femasys secures FDA approval to advance final FemBloc trial phase and $12 million financing, with potential to reach $58 million. News release. Femasys Inc. November 3, 2025. Accessed November 4, 2025. https://ir.femasys.com/news/news-details/2025/Femasys-Secures-FDA-Approval-to-Advance-Final-FemBloc-Trial-Phase-and-12-Million-Financing-with-Potential-to-Reach-58-Million/default.aspx
2. Liu JH, Blumenthal PD, Castano PM, et al. FemBloc non-surgical permanent contraception for occlusion of the fallopian tubes. J Gynecol Reprod Med. 2025;9(1):1-12. https://www.opastpublishers.com/open-access-articles/fembloc-nonsurgical-permanent-contraception-for-occlusion-of-the-fallopian-tubes.pdf.